The role of a board member is often reduced to oversight. Financial reports are reviewed, governance standards are enforced, and compliance is monitored. For Leen Kawas, co-founder and managing general partner of Propel Bio Partners, the responsibility goes further. Drawing on her experience as a scientist, inventor, and entrepreneur, she views board service as an opportunity to add strategic value that shapes the future of an organization.
Beyond Oversight
Kawas has seen the life sciences industry from multiple vantage points. As the co-founder and former chief executive of Athira Pharma, she led a company through clinical development and an initial public offering that raised more than $400 million. At Propel Bio Partners, she invests in biotech ventures and advises their leadership. Across these experiences, she has come to believe that a board must do more than react to management’s updates.
For Kawas, adding value means engaging deeply with strategy. This involves asking questions that reveal blind spots, offering insights from past challenges, and helping to refine goals. She emphasizes that the best boards act as partners in growth, bringing perspective that complements operational leadership.
Science at the Table
One of Kawas’s unique contributions as a board member is her scientific background. Many boards in the biotech sector are dominated by finance or legal expertise. Kawas argues that scientific literacy is equally essential, especially for companies whose futures hinge on clinical success.
Her training as a pharmacist and researcher allows her to evaluate technical risks and opportunities with precision. This perspective enables boards to make more informed decisions about timelines, partnerships, and portfolio priorities. Kawas believes that when science is part of the conversation, boards are better equipped to align strategy with reality.
Supporting Leadership
Adding value also means supporting executives without replacing them. Kawas stresses that board members must respect management’s role while providing guidance grounded in experience. She recalls her own time as a chief executive, noting that the most helpful directors were those who combined accountability with mentorship.
She applies this lesson by focusing on constructive dialogue. When challenges arise, she works to frame them as opportunities for improvement rather than purely as criticisms. By building trust with leadership, she creates space where candid conversations can occur. This partnership strengthens the organization’s ability to adapt and grow. Check out her bio on Eit Pharma to learn more.
Connecting Capital and Vision
Kawas also highlights the board’s role in linking capital to vision. Investors expect returns, but sustainable success depends on more than financial performance. It requires clear articulation of mission and long-term strategy.
Her experience raising funds and taking a company public gives her insight into what investors need to see. She helps companies position themselves in ways that attract capital while staying true to their scientific and social goals. This alignment between purpose and profit, she argues, is one of the most valuable contributions a board member can make.
Preparing for Scale
Biotech ventures often begin with narrow focus, but growth demands scalability. Kawas brings a forward-looking lens to board discussions, encouraging teams to consider how today’s choices will impact tomorrow’s expansion. This might involve evaluating whether manufacturing processes can scale, whether partnerships are flexible enough to evolve, or whether talent pipelines are strong enough to support growth.
Her strategic input reflects a conviction that scaling is not just about adding size but about building resilience. Boards that anticipate the challenges of growth help companies avoid the pitfalls of short-term thinking.
Building Ecosystems
For Kawas, board service extends beyond the company itself. She views each role as part of a broader ecosystem of innovation. By connecting companies with networks of researchers, investors, and entrepreneurs, she helps them access resources that accelerate progress.
This ecosystem mindset is central to Propel Bio Partners, where the goal is not only to fund ventures but also to surround them with the expertise they need to succeed. Leen Kawas brings that same perspective to boardrooms, ensuring that companies are not isolated but embedded in communities that sustain innovation.
Looking Ahead
As biotech continues to advance, the demands on boards will grow. Scientific complexity, regulatory scrutiny, and global competition create challenges that cannot be solved through governance alone. Kawas’s philosophy points to a different model, where board members actively contribute to strategic clarity, operational resilience, and long-term vision.
Her approach underscores that a board’s true value lies in shaping outcomes, not just recording them. By blending scientific knowledge, entrepreneurial experience, and investment insight, Kawas adds a dimension that few can match. She sees board service not as a ceremonial role but as a responsibility to guide companies toward meaningful impact.
Leen Kawas’s career demonstrates that when board members lean into strategy, they help organizations navigate uncertainty with confidence. Her work reminds us that in industries as dynamic as biotechnology, oversight alone is insufficient. To build companies that endure, boards must also build value.
To learn more about how Leen Kawas works, check out her interview with Billions Success:
Leave a Reply